HOUSE_OVERSIGHT_024692.jpg
2.1 MB
Extraction Summary
0
People
5
Organizations
1
Locations
0
Events
0
Relationships
3
Quotes
Document Information
Type:
Investment report / market analysis
File Size:
2.1 MB
Summary
This document is page 56 of a December 2017 Cannabis Investment Report produced by Ackrell Capital, LLC. It analyzes risks regarding FDA approval and product liability, outlines the outlook for consumer products (flower, edibles, etc.), and discusses business solutions and software within the cannabis industry. The document bears a 'HOUSE_OVERSIGHT_024692' Bates stamp, indicating it was part of a document production for a House Oversight Committee investigation.
Organizations (5)
| Name | Type | Context |
|---|---|---|
| Ackrell Capital, LLC | ||
| FDA | ||
| FINRA | ||
| SIPC | ||
| House Oversight Committee |
Locations (1)
| Location | Context |
|---|---|
Key Quotes (3)
"Assuming that cannabis-derived drugs will eventually be permitted to be sold in the United States, considerable time and expense will be spent by manufacturers to obtain FDA approval and bring approved products to market."Source
HOUSE_OVERSIGHT_024692.jpg
Quote #1
"Consumer claims that products cause injury or illness... may be expensive to defend or settle."Source
HOUSE_OVERSIGHT_024692.jpg
Quote #2
"Software and services providers in this segment generally do not “touch the plant” and do not require cannabis-related permits or licenses."Source
HOUSE_OVERSIGHT_024692.jpg
Quote #3
Discussion 0
No comments yet
Be the first to share your thoughts on this epstein document